Anavex Life Sciences' (AVXL) stock surged on new Alzheimer's trial data, but data's inconsistency raises concerns, making the ...

Biogen (NASDAQ: BIIB) Q3 2024 Earnings Call Oct 30, 2024, 8:30 a.m. ET ...

Eisai (ESAIY) completes BLA submissions for an injectable version of its Biogen (BIIB)-partered Alzheimer's drug Leqembi in ...

Biogen expects annual adjusted profit per share of $16.10 to $16.60, compared with a $15.75 to $16.25 per-share range ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business ...

The annual meeting of the American Society of Nephrology (Kidney Week) was held this year from Oct. 23 to 27 in San Diego, ...

Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...

The application covers a once-weekly autoinjector formulation of the anti-amyloid antibody Leqembi (lecanemab), after a ...

Biogen and Neomorph have partnered to discover and develop molecular glue degraders for treating Alzheimer’s and other rare ...

Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven ...

Biogen Inc BIIB reported upbeat earnings for the third quarter on Wednesday. The company pisted third-quarter adjusted EPS of ...